trending Market Intelligence /marketintelligence/en/news-insights/trending/1tqtcUxBVB3r1_hRCRh7qA2 content esgSubNav
In This List

Qiagen's molecular testing system cleared by US FDA

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


Qiagen's molecular testing system cleared by US FDA

Qiagen NV said the U.S. Food and Drug Administration granted 510(k) clearance to its molecular diagnostic system QIAstat-Dx.

The Netherlands-based company developed QIAstat-Dx syndromic testing system to detect and identify multiple respiratory viral and bacterial pathogens.

Qiagen launched the QIAstat-Dx syndromic testing system together with its multiplex QIAstat-Dx respiratory panel.